Humana (HUM)
(Delayed Data from NYSE)
$279.45 USD
-37.29 (-11.77%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $278.50 -0.95 (-0.34%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$279.45 USD
-37.29 (-11.77%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $278.50 -0.95 (-0.34%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth B Momentum C VGM
Zacks News
Humana (HUM) Partners With UAB to Boost Care for MA Members
by Zacks Equity Research
Humana (HUM) expands its Medicare Advantage network in Alabama through a new partnership with UAB Health System, offering greater access to enhanced healthcare services.
Do Options Traders Know Something About Humana (HUM) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Humana (HUM) stock based on the movements in the options market lately.
Why Is Humana (HUM) Up 13.1% Since Last Earnings Report?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks Industry Outlook Highlights UnitedHealth, The Cigna, Centene and Humana
by Zacks Equity Research
UnitedHealth, The Cigna, Centene and Humana have been highlighted in this Industry Outlook article.
Ensign Group (ENSG) Stock Down 2.4% Despite Q1 Earnings Beat
by Zacks Equity Research
Ensign Group (ENSG) expects revenues between $4.13 and $4.17 billion, the mid-point of which indicates an improvement of 11.3% from the 2023 figure.
4 HMO Stocks to Watch Amid Persistent Industry Challenges
by Debasmita Chatterjee
The Medical-HMO industry continues to witness an expanding customer base resulting from contract wins. However, high technology expenses and a shortage of medical personnel are a concern. UNH, CI, CNC and HUM are likely to navigate industry storms.
Cigna (CI) Q1 Earnings Beat on Client Wins in Evernorth Unit
by Zacks Equity Research
Cigna's (CI) Q1 results reflect strong organic growth in the Evernorth Health Services unit. It expects adjusted EPS of at least $28.40 for 2024, up from the earlier guidance of at least $28.25.
Investors Heavily Search Humana Inc. (HUM): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Humana (HUM). This makes it worthwhile to examine what the stock has in store.
Encompass Health (EHC) Stock Down Despite Q1 Earnings Beat
by Zacks Equity Research
Encompass Health (EHC) increases its guidance for net operating revenues, which is in the range of $5.25-$5.325 million for 2024.
Centene (CNC) Q1 Earnings Beat on Premiums, '24 EPS View Hiked
by Zacks Equity Research
Centene's (CNC) Q1 results reflect strength in the Commercial business line. Management currently expects adjusted EPS to be greater than $6.80 for 2024.
Molina Healthcare (MOH) Q1 Earnings Beat on Growing Membership
by Zacks Equity Research
Molina Healthcare's (MOH) Q1 results reflect strong premium revenue growth. It continues to estimate adjusted EPS at a minimum of $23.50 for 2024.
Humana (HUM) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)
by Zacks Equity Research
Although the revenue and EPS for Humana (HUM) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Premium Growth Propels Humana (HUM) to Easy Q1 Earnings Beat
by Zacks Equity Research
Humana (HUM) bumps up individual Medicare Advantage membership growth guidance.
Humana (HUM) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Humana (HUM) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Humana (HUM) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 20.10% and 2.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Humana (HUM)
by Zacks Equity Research
Humana (HUM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Watch These 5 Medical Stocks for Q1 Earnings: Beat or Miss?
by Debasmita Chatterjee
Improved premiums resulting from membership growth, and higher patient admissions are expected to have driven the Q1 performance of HUM, MOH, UHS, EHC and CYH. An elevated operating expense level is likely to have dented growth prospects.
Will Humana (HUM) Q1 Earnings Beat on CenterWell Strength?
by Zacks Equity Research
Humana's (HUM) first-quarter results are likely to reflect rising premiums and investment income.
Analysts Estimate Centene (CNC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Centene (CNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Analyst Projections for Key Metrics Reveal About Humana (HUM) Q1 Earnings
by Zacks Equity Research
Evaluate the expected performance of Humana (HUM) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Humana (HUM) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Humana (HUM) closed the most recent trading day at $324.83, moving +0.42% from the previous trading session.
Humana (HUM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Humana (HUM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Brokers Suggest Investing in Humana (HUM): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Humana (HUM). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Humana (HUM) Stock Moves -1.17%: What You Should Know
by Zacks Equity Research
In the latest trading session, Humana (HUM) closed at $312.59, marking a -1.17% move from the previous day.